All In MedTech

Device Trial Radar · NCT03066700

Prognostic Factors in Malignant GI Bleeding Treated With Hemostatic Powder

Prognostic Factors of Outcome in Patient With Malignant Gastrointestinal Bleeding Treated With a Novel Hemostatic Power

Last checked: Nov 19, 2026Latest source record: Feb 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

90

Actual

Start

Mar 1, 2017

Primary completion

Jun 1, 2017

Study completion Aug 31, 2017

Sponsor

Lead sponsor
King Chulalongkorn Memorial HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
McGill University
First posted
Feb 28, 2017

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a retrospective study to identify the prognostic factors of the good outcomes in patients who presented with upper GI bleeding from tumor and received Hemospray via endoscopy for hemostatic control. The good outcomes were assessed by immediate hemostasis, rebleeding at 72 hours as well as 7, 14 and 30 days following presentation at initial bleeding episode and also 6-month survival rate.

Conditions

  • Death

Interventions

  • Hemostatic powderDevice

    HemosprayTM (Tc-325) is an endoscopic hemostatis powder that came onto market recently. It is made of an inorganic, non-absorbable powder which acts locally at the mucosa. When spraying the powder on to the bleeding site, it creates an adherent stable barrier sheath that allows for at least temporary hemostasis. Neither luminal nor systemic side effects have been reported to date.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mortality rateTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • King chulalongkorn memorial hospita

    Bangkok, Pathum Wan, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.